Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

BioFocus and Usher III Inititative ink drug discovery deal
October 2010
SHARING OPTIONS:

SAFFRON WALDEN, U.K.BioFocus and the Usher III Initiative Inc. announced in September that they have embarked on a drug discovery project focused on Usher Syndrome Type III, a rare genetic disorder that causes the loss of hearing and vision.
 
Three subtypes of Usher Syndrome, identified as I, II and III, vary greatly in clinical symptoms and disease onset: Type I shows the most profound impact on hearing and vision, whereas Types II and III are generally milder, with onset occurring later in life.
 
Under the agreement, BioFocus will perform an integrated program encompassing medicinal chemistry and biological sciences. Further details were not disclosed.
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.